Medtronic plc. Ordinary Shares (MDT) Covered Calls

Medtronic plc. Ordinary Shares covered calls Medtronic plc is a global leader in healthcare technology, providing innovative medical device solutions for over 70 health conditions. It operates across four primary segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. Known for its battery-powered portable pacemaker legacy, the company now integrates AI and data analytics into life-saving therapies. Medtronic focuses on alleviating pain and restoring health for millions of patients in more than 150 countries.

You can sell covered calls on Medtronic plc. Ordinary Shares to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for MDT (prices last updated Fri 2:20 PM ET):

Medtronic plc. Ordinary Shares (MDT) Stock Quote
Last Change Bid Ask Volume P/E Market Cap
100.24 -0.64 100.24 100.26 5.5M 27 129
Covered Calls For Medtronic plc. Ordinary Shares (MDT)
Expiration Strike Call Bid Net Debit Return
If Flat		 Annualized
Return If Flat
Feb 20 100 2.30 97.96 2.1% 95.8%
Mar 20 100 3.40 96.86 3.2% 32.4%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls?  Sign Up For A Free Trial

Medtronic plc (MDT) is the world’s largest pure-play medical technology company. Headquartered in Ireland with significant operations globally, it is dedicated to its mission of "alleviating pain, restoring health, and extending life." The company has transformed from a device-centric manufacturer into a technology-driven healthcare partner, leveraging a massive data ecosystem and artificial intelligence to improve clinical outcomes and operational efficiency across the continuum of care.

Core Business and Portfolios

  1. Cardiovascular Portfolio: This is Medtronic’s largest division, encompassing Cardiac Rhythm and Heart Failure, Structural Heart and Aortic, and Coronary and Peripheral Vascular. In early 2026, the segment is being driven by the rapid adoption of its Pulsed Field Ablation (PFA) portfolio for atrial fibrillation and the commercial success of the Evolut FX heart valve system.
  2. Neuroscience Portfolio: This segment includes Cranial and Spinal Technologies, Neuromodulation, and Specialty Therapies. In 2026, the AiBLE spine technology ecosystem, which integrates robotics, navigation, and data analytics, is a major growth driver, alongside next-generation spinal cord stimulators for chronic pain management.
  3. Medical Surgical Portfolio: Focusing on surgical innovations and patient monitoring, this segment is leading the charge in robotic-assisted surgery with the Hugo system. Medtronic is also integrating the GI Genius intelligent endoscopy module, powered by AI, to enhance colorectal cancer screening.
  4. Diabetes: The company provides advanced insulin delivery systems and continuous glucose monitoring (CGM). In early 2026, Medtronic announced a major milestone by expanding its MiniMed Go smart system, which features sensors developed in a landmark cross-industry partnership to improve the "closed-loop" experience for patients.

Competitive Landscape

Medtronic competes in a highly technical and regulated global arena. Its primary rivals in the cardiovascular and diagnostics space include Abbott Laboratories and Boston Scientific. In the surgical robotics and orthopedics sectors, it faces intense competition from Intuitive Surgical and Stryker. For broader medical devices and surgical tools, it contends with Johnson & Johnson. In the structural heart market, Edwards Lifesciences remains a key adversary, while DexCom is a primary competitor within the diabetes technology landscape.

Strategic Outlook and Innovation

In 2026, Medtronic is executing an "Innovation Acceleration" strategy, marked by the intent to acquire CathWorks to integrate AI-driven coronary physiology platforms into its cardiology suite. The company is pivoting toward "Agentic AI" applications to automate diagnostic workflows and personalize therapy delivery in real-time. A major strategic focus this year is the internal reorganization of the Diabetes business to operate with greater agility, following the successful rebranding of its upcoming independent initiatives. Management continues to prioritize efficiencies in its global supply chain and manufacturing footprint to drive structural margin expansion. Financially, Medtronic remains a cornerstone for income investors, as it recently marked nearly half a century of consecutive annual dividend increases. By investing heavily in high-growth markets like pulsed field ablation and surgical robotics, the company aims to sustain durable, mid-single-digit organic growth while advancing its role as the lead architect of the future of healthcare technology.